摘要:
The invention concerns benzothiazoles and benzoxazoles of generale formula (I), in which R1 to R3, X, Z and n are as defined in claim 1, their enantiomers, diastereomers and salts thereof, in particular physiologically tolerated acid addition salts, which exhibit biosynthesis of cholesterol. The invention also concerns drugs containing these compounds, their use and methods of preparing them.
摘要:
The invention concerns a sampling device in which the boundary with the microbiologically contaminated environment takes the form of a sterile protective gas stream with 'laminar air flow' characteristics underneath a housing bell (7); the connection point between the inner tube (11) and the sample tube (10) is at a point inside or just underneath the bell (7), with or without a fixed connection, and for automatic operation just underneath the bell (7) without a fixed connection.
摘要:
Cyclic urea derivatives having the general formula (I), in which R1 to R9, Ra, Rb, A, D, E and F have the definitions given in the first claim, their tautomers, their stereoisomers, including their mixtures and their salts, in particular their physiologically acceptable salts with inorganic or organic acids or bases, have valuable pharmacological and other properties, preferably aggregation-inhibiting effects. Also disclosed are medicaments containing said compounds, their use and a process for producing the same.
摘要:
Die vorliegende Erfindung betrifft Piperazinderivate der allgemeinen Formel
in der R a , Y₁ bis Y₃ und E wie Anspruch 1 definiert sind, deren Tautomere, deren Stereoisomere, einschließlich ihrer Gemische, und deren Salze, insbesondere deren Salze mit physiologisch verträglichen Säuren oder Basen, welche wertvolle pharmakologische Eigenschaften aufweisen, vorzugsweise aggregationshemmende Wirkungen, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu ihrer Herstellung.
摘要:
New aminoacid derivates have the general formula: T-Z-NR?1-(R2CR3¿)-CO-Y-(CH¿2?)n-R, in which R, R?1 to R3¿, T, Z, Y and n are defined as in the first claim. They represent valuable NPY-antagonistic active substances. Also disclosed are their diastereomers, their enantiomers and their salts, in particular their physiologically tolerable salts with inorganic or organic acids or bases, as well as medicaments containing these compounds, their use and a process for preparing the same.